QB3 Seminar: Meytal Waiss, FreeMind. "Beyond the SBIR: Non-Dilutive Funding for Your Startup"

Billions of non-dilutive dollars are awarded annually across scientific fields, mainly from NIH, DOD, and other government sources. In 2016 alone, domestic for-profit organizations received approximately $2.7 billion from awards ranging from $200k to multi-millions; ~$2 billion came from non-SBIR funders. In this presentation, Meytal Waiss of the FreeMind Group will give an overview of the non-dilutive funding landscape with an emphasis on NIH, DOD, and BARDA. She will discuss alternatives to SBIR/STTR, and describe the various mechanisms and pockets of money available, potential for funding, and means to maximize your chances of winning an award.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

12:00-1:00 pm, Thursday, June 15

Eventbrite - QB3 Seminar: Meytal Waiss, FreeMind. "Beyond the SBIR: Non-Dilutive Funding for Your Startup"

About the Speaker

Meytal Waiss FMG.jpg

Meytal Waiss, Director of Business Development at FreeMind, has spent most of her career as a part of the scientific community. Previously a Senior Project Manager in FreeMind’s Professional Department, Meytal has helped clients manage the complex application production process, submit, and win, and is now utilizing her strong background in the life sciences, grant writing, and understanding of non-dilutive funding to guide potential clients through the first stages of the process. Meytal holds a Master’s degree in Cellular and Developmental Biology from the Hebrew University of Jerusalem, where she specialized in Neurodegenerative Diseases and Microscopy.

Rosenman D-Series: Marijke Annis, Ruckus Partners. "Reimbursement 101 for Medtech Startups"

Regulatory approval no longer guarantees market access. Payers control the health care dollar and ultimately if and how patients access new technologies. Understanding the reimbursement challenges your technology may face and setting a strategy early in the product development process will help ensure you can navigate payer challenges. Attendees will leave with an understanding of the current U.S. reimbursement system and how to navigate coding, payment and coverage.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

5:00-7:00 pm, Thursday, May 18

Eventbrite - D-Series: Marijke Annis, Ruckus Partners. "Reimbursement 101 for Medtech Startups"

Agenda

5:00-6:00 pm: Talk and Q&A

6:00 pm onward: Networking

About the Speaker

Marijke Annis Headshot 2015 72dpi.jpg

Marijke Annis, MSPH, Founder, is a reimbursement expert whose work has realized multiple, positive coverage and payment decisions for innovative medical solutions across devices and diagnostics. Having worked in payer relations for integrated health delivery systems, she offers a unique ‘inside-payer’ perspective that serves to shape these successful strategies. Prior to founding Ruckus Partners, she held leadership positions for companies and health care providers across the market - hospital and physician groups, diagnostics and medical devices and she knows cardiology, women’s health, oncology, hematology, pulmonology, and ophthalmology. Her former roles include reimbursement leadership for CardioDx, Abbott Vascular, and Guidant, and in managed care for Tenet Health Care.

Marijke received a MSPH from the University of North Carolina Chapel Hill and a BA from Emory University.

Leadership in Biopharma: a Conversation with John Milligan, CEO, Gilead Sciences

Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, CEO of Threshold Pharmaceuticals and himself a former UCSF postdoc, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products.

Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.

Where and When

Byers Auditorium, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)

4:00-5:00 pm, Thursday, May 11

Eventbrite - A Conversation with John Milligan, CEO, Gilead Sciences

Agenda

4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers

4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, Threshold Pharmaceuticals

5:00-6:30 pm Reception

About the Speakers

Dr. John F. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He began his career at Gilead as a research scientist, and subsequently held leadership positions in project management and corporate development before being named Chief Financial Officer in 2002. He was appointed Chief Operating Officer in 2007 and President in 2008.

During his tenure at Gilead, Dr. Milligan has led teams that have developed, manufactured and commercialized more than 20 new therapies for significant unmet needs. He has managed multiple transformative acquisitions, licensing agreements and financings, helping the company grow into a worldwide organization reaching more than 10 million patients. He is a member of the board of Pacific Biosciences of California, Inc. and a Trustee of Ohio Wesleyan University.

Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company that was acquired by ArQule. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

bbyerslowres200.jpg

Brook Byers is a Founding Partner of Kleiner Perkins Caufield & Byers. A venture capital investor since 1972, Brook has been closely involved with more than 60 new technology-based ventures, many of which have become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare and biotechnology sectors. KPCB has invested in and helped build more than 170 life sciences companies that have developed hundreds of products to treat underserved medical needs for many millions of patients. Brook was the founding president and then chairman of four biotechnology companies that were incubated in KPCB’s offices and went on to become public companies with an aggregate market value of more than US$8 billion. He serves on the board of directors of Cell Design Labs, Enjoy, Newsela and Zephyr Health. Brook is also a Lifetime Director on the UCSF Board of Overseers. Full bio on KPCB website

Rosenman D-Series: Laura Parmer-Lohan, Ruckus Partners. "So, You Want to Go to Market in Medtech. Now What?"

There are many decisions to be made from now until launch. This discussion will cover the role of product marketing in medtech and the critical milestones for preparing your product for launch, from crafting a compelling value proposition to developing strategies for the key stakeholders involved in the buying process. Attendees will leave with a clear overview of how product marketing can be used as a strategic element in a company’s long term success.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

5:00-7:00 pm, Thursday, April 13

Eventbrite - D-Series: Laura Parmer-Lohan, Ruckus Partners. "So, You Want to Go to Market in Medtech. Now What?"

Agenda

5:00-6:00 pm: Talk and Q&A

6:00 pm onward: Networking

About the Speaker

Laura Parmer-Lohan, MBA, is a founder of Ruckus Partners a consulting firm specializing in marketing and reimbursement for medtech innovation. She is a marketing leader who has demonstrated capabilities from product portfolio strategy development to product launch to revenue generating product lifecycle marketing. Laura specializes in uncovering customer needs and connecting this with the product marketing strategy to motivate the customer to action. She has led or participated in the launch of more than 24 products from cardiovascular therapeutic devices, type 2 diabetes first-in-class biopharmaceutical to specialty oncology reference lab test services and digital health apps.

Laura is an advisor for LaunchPad Digital Health, FAST program mentor for California Life Sciences Association, guest instructor for UCSF/UCB MTM Program and Haas School of Business MBA/MPH Program and the events co-lead for MedtechWomen.

Her former roles include marketing leadership at diaDexus, Sequenta, Genoptix (now Novartis), Amylin (now AstraZeneca), and Guidant (now Abbott Vascular). She received her MBA from UC Berkeley, Haas School of Business, and her bachelor of arts from UC Santa Cruz.

QB3 Seminar: Ryan Davison, ACS. "How Federal Politics Impact Funding for Science and Startups"

Washington politics usually seem far removed from life at the lab bench. But issues at the federal level can affect what funds the government makes available for grants of all types, from R01 to SBIR. If you understand the ever-changing landscape, you may be able frame your application so it is successful, or expand into research areas that are more likely to get funded. To get the big picture from Ryan Davison, government affairs manager at the American Chemical Society in Washington, DC, join us on April 3. Ryan will provide a general political update, highlight specific pieces of legislation meaningful to researchers, discuss key congressional committees, and explain how Republicans and Democrats view the economy differently. Additionally, Ryan will take a look at SBIR and proof-of-concept funding, and highlight areas likely to get funding in the near future.

Where and When

Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)

Noon to 1:00 pm, Monday, April 3

Eventbrite - QB3 Seminar: Ryan Davison, ACS. "How Federal Politics Impact Funding for Science and Startups"

About the Speaker

Dr. Ryan Davison is currently the Manager of Government Affairs at the American Chemical Society where he advocates for legislation that supports the chemical industry. Dr. Davison manages advocacy and policy development on priority issues including manufacturing, tax and trade, intellectual property, patents, biomedical research, innovation and competitiveness, agency funding, and appropriations. Most of his time is spent on Capitol Hill meeting with lawmakers and their staff, attending Congressional hearings and mark-ups, and monitoring bills relevant to the chemical enterprise. Ryan possesses a distinct background of policy and science experience. Before joining the ACS he worked as a policy Fellow at the National Academy of Sciences, served as Biosecurity Analyst at the Federation of American Scientists, was a post-doctoral Fellow at Georgetown University, and an adjunct professor at George Washington University. He holds and Bachelor's and Master's degree in Psychology from Appalachian State University, a Ph.D. in Neuroscience from the University of Alabama at Birmingham (UAB), and is in a unique position to be able to personally highlight the importance of innovation and research to members of Congress and their staff.

QB3 Seminar: David Spellmeyer. "Score! How Your SBIR/STTR Application is Reviewed and Scored"

The SBIR/STTR grant review process can be extremely frustrating and opaque. But if you understand how the reviewers operate, you can improve the chances that your application will succeed. On March 23, David Spellmeyer, an expert SBIR consultant, will reveal the inner workings of an SBIR/STTR Study Section Review Panel. David’s talk will cover panel composition, review assignments, meeting mechanics, critiques, and the scoring process. Join us to learn several ways that you can make your application stand out.

About the Speaker

David Spellmeyer, Ph.D., is Principal at Interlaken Associates, a consulting firm working with early stage companies on a wide variety of projects, including SBIR/STTR support. David is a regular member of SBIR/STTR Study Sections and recently served as Chair of the IMST-14 Study Section - Small Business: Computational, Modeling, and Biodata Management.

David brings his clients broad technical and business expertise gained in companies both small and large. He has been involved in the development of several technologies as a scientist, including combinatorial chemistry, label free screening, and translational applications of single-cell functional pathway analysis. Development of these technologies required overcoming many difficult steps of standardization, qualification, and validation of components of laboratory and information systems for use in clinical applications.

David works very closely with business development teams and has been involved in establishing over 20 non-dilutive strategic corporate partnerships, 4 mergers and acquisitions, several rounds of venture financing, one joint venture. He is an Adjunct Associate Professor at UCSF and an active mentor at UCSF’s Entrepreneurship Center, California Life Sciences Institute’s FAST Program, and OneStart Americas.

QB3 Seminar: "US Immigration Policy in Flux: How it Affects Scientists, Startups, and You." Atessa Chehrazi & Sang Kim, Jackson Hertogs

View the video of this talk

More than half of the startups in the QB3 network were founded by entrepreneurs not born in the US. And, at some point, many startups hire foreign scientists because of their specialized skills. But the procedures for applying for immigrant and non-immigrant visas, which have never been simple, have become more complicated since Donald Trump was elected president. To learn more about how Trump’s executive orders, and recent bills introduced in Congress, may affect your company’s hiring or your own employment prospects—and to get a refresher on the US immigration system, with a biotech focus—join us on March 2 for a special talk by Atessa Chehrazi and Sang Kim from the immigration law firm of Jackson & Hertogs.

Where and When

Noon to 1:00 pm, Thursday, March 2

Room N-114, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)

About the Speakers

Atessa Chehrazi

Atessa023.JPG

Atessa has been a partner at Jackson & Hertogs since April 2013 and an associate/senior associate since July 2000. She was previously an associate at Maggio & Kattar in Washington, D.C. from 1996 to 2000. She has held several volunteer roles within the American Immigration Lawyers Association (AILA) during her career. For AILA’s Northern California Chapter, she has served as Chair, Vice-Chair, Treasurer, U.S. Citizenship & Immigration Service (USCIS) liaison, and Customs & Border Protection (CBP) liaison. On a national level, Atessa served on AILA’s USCIS Headquarters and Benefits, Administrative Appeals Office (AAO), and Department of Labor (DOL) liaison committee. In addition, Atessa has served on AILA’s Business Immigration Advocacy, Issues, and Due Process & Civil Liberties committees, as well as several conference committees. She has served as a board member of the Iranian American Bar Association Northern California chapter since 2009 and is incoming President of the chapter. She is a member of the Bar Association of San Francisco, and the National Lawyers Guild. She has authored several articles published in AILA Handbooks. Atessa has presented at national and regional AILA conferences. Atessa has been highly reviewed in legal directories, including selection as a Northern California “Super Lawyer” (2010-2012), and listing in the International Who’s Who of Corporate Immigration Lawyers (2011-2015).

Sang Kim

Sang joined Jackson and Hertogs as a Senior Associate in December 2015. He possesses over a decade of experience in immigration, nationality and global business law. Sang has guided corporate, entrepreneur and investor clients in all aspects of temporary and permanent visa, travel and employment matters. He has also represented hundreds of scientists, performers, executives and extraordinary individuals in the field on their personal immigration petitions. Previously, Sang was a former Congressional Staff member to then, U.S. Senator and Secretary of State Hillary Clinton. Admitted to the New York State Bar since 2005, he is a graduate of New York University and Brooklyn Law School and is a current and active member of AILA.